A new study has raised serious concerns for people with type 2 diabetes, suggesting that stopping a popular class of drugs, known as GLP-1 agonists, could nearly double their risk of suffering a heart attack, stroke, or dying from any cause.
What the New Study Found
Researchers
in Italy analyzed the health records of over 80,000 people with type 2 diabetes who did not have pre-existing cardiovascular disease. The study, published in The Lancet Regional Health - Europe, compared those who continued taking GLP-1 medications with those who stopped. The results were stark: discontinuing the treatment was linked to approximately twice the risk of a major cardiovascular event. Specifically, the rate of events like heart attacks or strokes was about four per 100 people per year among those who stopped, compared to just two per 100 people per year for those who continued the therapy. The association was even more pronounced in patients with obesity.
The Drugs in Question
The medications at the center of this research are Glucagon-like peptide-1 (GLP-1) receptor agonists. This class of drugs, which includes well-known brands like Ozempic, Wegovy, and Trulicity, has become a cornerstone of modern diabetes and obesity treatment. They work by mimicking a natural hormone that helps regulate blood sugar, reduces appetite, and has been proven to offer significant benefits for heart and kidney health. The Italian study primarily involved older GLP-1 drugs like liraglutide and dulaglutide, as newer, more potent versions like semaglutide (Ozempic) and tirzepatide (Mounjaro) entered the market later. However, other studies focusing on these newer drugs have shown similar patterns, where stopping treatment erodes the cardiovascular protection gained.
Why Does Stopping Increase the Risk?
The study raises a crucial question: is the increased risk caused directly by stopping the drug, or are other factors at play? The authors note that this was an observational study, meaning it can't prove direct causation. It’s possible that patients who stopped the medication were already in poorer health for other reasons. However, one surprising finding was that changes in weight, blood pressure, and blood sugar were only modest after discontinuation and didn't fully explain the jump in risk. This suggests the protective effects of GLP-1 drugs on the cardiovascular system may be more direct and are lost once the medication is no longer active in the body. One expert described the effect of stopping as a 'metabolic whiplash', where inflammation, blood pressure, and cholesterol can rebound, negatively impacting heart health.
A Call for Long-Term Treatment
Despite their proven benefits, a large number of patients stop taking these drugs, often within the first year, due to side effects, cost, or supply shortages. This new research underscores the idea that GLP-1 agonists aren't a shortterm fix but a longterm management strategy for a chronic condition. The cardiovascular benefits appear to accumulate with continuous use and can be lost surprisingly quickly—with risks beginning to rise just six months after stopping. One study on US veterans found that after two years off the medication, the risk of a major cardiovascular event was up to 22% higher than for those who continued treatment, effectively erasing the protection gained.
What This Means for Patients in India
For the millions of people in India living with type 2 diabetes, this study provides a critical message: do not stop your medication without a thorough discussion with your doctor. While GLP‑1 drugs are becoming more common in India, understanding their role in long‑term health is vital. The findings suggest that consistent, uninterrupted use is key to maintaining their powerful heart‑protective benefits. If you are considering stopping due to side effects or other concerns, it's essential to work with your healthcare provider to find a safe alternative or a plan to manage your risks. These medications are not a temporary cure but a vital tool for managing a lifelong condition and safeguarding your cardiovascular health.
